Pharma Focus Asia

Sanofi Invests US$470 million to Strengthen Vaccines Manufacturing Capacities

Introduction:

Sanofi plans to build a new vaccine production site in Singapore with an investment of US$470 million (€400 million).

Features:

The new production site complements the current manufacturing facilities in Europe and North America and will grow up as a regional center of excellence for the production of vaccines in Asia.

The new production site will be designed around a central unitfeaturing several fully digitalised modules. In addition, the site designed with digitalised modules allows the production of three to four vaccines simultaneously, versus only one in current industrial sites.

Moreover, the facility will have the flexibility to leverage multiple vaccine manufacturing technology platforms based on different cell types and allow for faster production of vaccines.

The leading-edge production site will allow producing innovative vaccines on a large scale for Asia.The construction of the site is expected to start in Q3 2021, and fully operational in Q1 2026.

Specifications:

NameSanofi
TypeNew Construction
BudgetUS$470 million (€400 million)
Year2026
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference